Development of a next-generation DNA synthesis platform

Nuclera Nucleics Ltd is a Cambridge-based biotech start-up transforming the life sciencesthrough the development of a next generation DNA synthesis platform. Nuclera was foundedby four enterprising scientists determined to improve the slow and expensive process ofobtaining long pieces of biologically relevant DNA. Through our novel, biologically-inspiredtechnology we aim to furnish the life science community with rapid access to high accuracy, long DNA products such as plasmids and synthetic genomes made in the UK. This surge inpipeline efficiency will expand research horizons and help bring life-saving drugs to theglobal market faster.Building on a Smart Proof of Concept project where we established the power of our noveltechnology, we must now optimise and scale-up our process to approach commercialproduction. Key to achieving this goal is the development of a prototype for the automation ofour technology, which will be the cornerstone of our commercial instrumentation. A morerefined process and increased production capability will enable Nuclera to more swiftly meetthe growing market need for long strands of DNA. With our innovative synthesis platformand rapid development trajectory, we aim to establish Nuclera as the premium UK-basedprovider of long DNA strands worldwide.